Acute Myeloid Leukemia (AML) Clinical Trial
Official title:
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Verified date | March 2021 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open-label, Phase 1, dose-escalation (Segment 1) and expansion (Segment 2) study to determine the maximum tolerated dose (MTD) and/or the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of ABBV-744 in participants with relapsed/refractory Acute Myeloid Leukemia (AML).
Status | Terminated |
Enrollment | 30 |
Est. completion date | December 19, 2020 |
Est. primary completion date | December 19, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participant must have AML not amenable to curative therapy, refractory to standard of care therapy or for which standard of care therapy does not exist. Participants who are candidates for stem cell transplantation must have been offered this therapeutic option. - Must consent to provide biomarker analyses as described in the protocol. - Must have an Eastern Cooperative Oncology Group (ECOG) Performance status of: - Dose Escalation (Segment 1): 0 - 1 - Dose Expansion (Segment 2): 0 - 2 - Dose Escalation: Must have a serum albumin during Screening of >= 3.0 g/dL. - Participant has adequate bone marrow, renal and hepatic function. Exclusion Criteria: - Participant with known active Central Nervous System (CNS) disease. - Participant has received anti-cancer traditional medicine or anti-cancer herbal remedies within 14 days prior to ABBV-744 dosing. Saw palmetto is considered anti-cancer herbal remedy. Participant has received anti-cancer therapy within a period of 14 days or 5 half-lives (whichever is longer; except for immunotherapy where a period of 21 days will be acceptable) prior to Study Day 1. Except for hydroxyurea which will be allowed during screening and treatment for controlling leukocytosis. - Participant has been previously treated with a Bromodomain and Extra-Terminal (BET) inhibitor - Participant has unresolved clinically significant toxicities from most recent prior anti-cancer therapy, defined as any Common Terminology Criteria for Adverse Events (CTCAE v 4.03) grade 2 or higher clinically significant toxicity (excluding alopecia). - Participant has received the following within 7 days prior to the first dose of study drug: corticosteroid therapy, CYP3A inhibitors, CYP3A inducers. - Participant consumed grapefruit or grapefruit products within 3 days prior to the first dose of study drug. - Participant had major surgery within 28 days prior to Study Day 1. - Participant is unable to swallow or absorb oral tablets. - Participant has known infection with hepatitis B or hepatitis C. - Participant has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis, enteritis, colitis. - Participant has symptoms of gross hematuria or gross hemoptysis - Has electrocardiogram with a QT interval corrected for heart rate using Fridericia's formula (QTcF) > 470 msec or ECG with second degree type 2 or third degree atrioventricular block. |
Country | Name | City | State |
---|---|---|---|
United States | Northwestern /ID# 171098 | Chicago | Illinois |
United States | University of Chicago DCAM /ID# 160702 | Chicago | Illinois |
United States | Cleveland Clinic Main Campus /ID# 160756 | Cleveland | Ohio |
United States | University of Texas MD Anderson Cancer Center /ID# 160701 | Houston | Texas |
United States | UC Irvine /ID# 160789 | Orange | California |
United States | University of California, Davis Comprehensive Cancer Center /ID# 202729 | Sacramento | California |
United States | Swedish-Center for Blood Disor /ID# 166487 | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
AbbVie |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum observed plasma concentration (Cmax) of ABBV-744 | Cmax of ABBV-744. | Through Cycle 2 ( each cycle is 28 days) | |
Primary | Time to Cmax (Tmax) of ABBV-744 | Tmax of ABBV-744. | Through Cycle 2 ( each cycle is 28 days) | |
Primary | Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration (AUCt) of ABBV-744 | Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration (AUCt) of ABBV-744. | Through Cycle 2 ( each cycle is 28 days) | |
Primary | Terminal Phase Elimination Rate Constant (ß) of ABBV-744 | Terminal Phase Elimination Rate Constant (ß) of ABBV-744. | Through Cycle 2 ( each cycle is 28 days) | |
Primary | Area under the plasma concentration-time curve (AUC) from time 0 to infinity (AUCinf) of ABBV-744 | Area under the plasma concentration-time curve (AUC) from time 0 to infinity (AUCinf) of ABBV-744. | Through Cycle 2 ( each cycle is 28 days) | |
Primary | Dose-limiting toxicity (DLT) of ABBV-744 | DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications and occurring during the first 4 weeks after administration of the first dose and that meets additional criteria as described in the protocol. | Up to 28 days after first dose of study drug | |
Primary | Maximum Tolerated Dose (MTD) for ABBV-744 | The MTD is defined as the highest dose for which the estimated posterior mean DLT rate is <= 33% and excessive toxicity probability is limited to maximum of 25% during the first 28 days. | Up to 28 days after first dose of study drug | |
Primary | Recommended Phase 2 Dose (RPTD) for ABBV-744 | RPTD will be determined from a review available safety, pharmacokinetic, and efficacy data during the dose escalation phase (Segment 1) of the study. | Up to 28 days after first dose of study drug | |
Secondary | Composite complete remission (CRc) | Percentage of participants who achieve composite complete remission (CRc), comprised of complete remission (CR) + CR with incomplete blood count recovery (CRi) is based on the International Working Group (IWG) criteria and European Leukemia Net criteria. | Up to 2 years | |
Secondary | Complete Remission (CR) + CR with partial hematologic recovery (CRh) | Percentage of participants who achieve CR + CR with partial hematologic recovery (CRh) is based on the International Working Group (IWG) criteria and European Leukemia Net criteria. | Up to 2 years | |
Secondary | Objective Response Rate (ORR) | Percentage of participants who achieve ORR [composite complete remission (CRc) + Partial remission (PR)] is based on the International Working Group (IWG) criteria (CRc, PR) and European Leukemia Net criteria. | Up to 2 years | |
Secondary | Duration of Response (DOR) | DOR is defined as the number of days from the date of first response to the first occurrence of progression or death from any cause, whichever occurs first. | Up to 2 years | |
Secondary | Event-free survival (EFS) | Percentage of participants who achieve EFS, where EFS is defined as the date of first dose of study drug to the date of primary refractory disease, relapse from CR or CRi, or death from any cause. | Up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04240002 -
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1/Phase 2 | |
Completed |
NCT02626715 -
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
|
Phase 2 | |
Completed |
NCT05488613 -
Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)
|
||
Completed |
NCT02265731 -
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
|
Phase 1/Phase 2 | |
Terminated |
NCT02927938 -
Leukemia Stem Cell Detection in Acute Myeloid Leukemia
|
Phase 3 | |
Completed |
NCT01772953 -
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
|
Phase 2 | |
Recruiting |
NCT03188874 -
Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
|
||
Completed |
NCT00071006 -
AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04079296 -
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
|
Phase 1/Phase 2 | |
Completed |
NCT04509622 -
A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)
|
Phase 3 | |
Withdrawn |
NCT03699384 -
Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
|
Phase 1/Phase 2 | |
Recruiting |
NCT03613532 -
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
|
Phase 1 | |
Terminated |
NCT02259348 -
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
|
Phase 2 | |
Completed |
NCT02252107 -
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1
|
Phase 2 | |
Terminated |
NCT01463410 -
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
|
N/A | |
Completed |
NCT01242774 -
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Terminated |
NCT02134782 -
Yoga Fatigue Study
|
N/A | |
Completed |
NCT01685619 -
AML-MDS Novel Prognostic Tests Clinical Study
|
||
Completed |
NCT03625505 -
A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
Active, not recruiting |
NCT04266795 -
A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy
|
Phase 2 |